undamentalytics Newsletter
Sign in

Grace Therapeutics, Inc. (GRCE) stock

Add to watchlist

Add holding +

NASDAQ: GRCE Nasdaq Pharmaceuticals Next results ~November 12, 2026

Grace Therapeutics, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in March.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders2 buying, 0 selling21 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds22 adding, 15 cuttingOf 7 active managers that changed their stake, 3 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 12, 2026 (estimated)

Current signal Several insiders buying shares: 2 insiders bought shares in the open market in the past 90 days, according to their Form 4 filings.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Results due soon. Results are expected around 12 November; the share price can move sharply on the day.
  • Volatile shares. Over the past year the shares showed annualised volatility of 72% and a beta of 0.9 against the S&P 500.

Latest results

Earnings per share
-$0.18 against an average estimate of -$0.18: beat by 1.0%
Share reaction
+2.9% in the first session after the results on August 13, 2026, against +0.5% for the S&P 500

Grace Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-6.7%
  • 1 week0.0%
  • 1 month-12.6%
  • This year-47.7%
  • 1 year-42.7%
  • 5 years-82.5%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 13, 2026
Next results (est.)
November 12, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Shareholder vote
  2. Results
  3. Agreement
  4. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Grace Therapeutics, Inc. valuation models and calculator

No model value for Grace Therapeutics, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Grace Therapeutics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.4%: the 10-year Treasury yield (4.9%) plus a beta of 0.99 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no twelve-month earnings or share count in the filings yet
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: no twelve-month earnings or share count in the filings yet
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: no twelve-month earnings or share count in the filings yet
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no twelve-month earnings or share count in the filings yet
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Grace Therapeutics, Inc. with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.76 −16% — 0%
Next −$0.64 +62% $7m 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −19.8% on 90 days ago. In the last 30 days, 0 analysts raised Grace Therapeutics, Inc.'s forecast and 1 cut it.

Consensus EPS forecast Grace Therapeutics, Inc., last 90 days
−$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.95 Current fiscal year, 60 days ago: −$0.95 Current fiscal year, 30 days ago: −$0.74 Current fiscal year, 7 days ago: −$0.74 Current fiscal year, Now: −$0.76 −$0.76 Next fiscal year, 90 days ago: −$0.79 Next fiscal year, 60 days ago: −$0.79 Next fiscal year, 30 days ago: −$0.77 Next fiscal year, 7 days ago: −$0.77 Next fiscal year, Now: −$0.64 −$0.64

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.95−$0.79
60 days ago −$0.95−$0.79
30 days ago −$0.74−$0.77
7 days ago −$0.74−$0.77
Now −$0.76−$0.64

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.18 −$0.18 +1.0%
Mar 2026 −$0.20 −$0.08 +58.9%
Dec 2025 −$0.39 −$0.19 +51.6%
Sept 2025 −$0.34 −$0.08 +75.6%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

2 analysts, Oct 2026
Buy2100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202622
  2. Sep 202622

Counts of recommendations published by analysts covering Grace Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
9.2%
of tradable shares
Days to cover
17.05
at average volume
Short interest, 1 month
−5%
to October 15, 2026
Held by institutions
32%
of shares
Held by insiders
18.7%
of shares
Employees
5
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
GRCE−52%−60%−4%+29%−8%−48%
Industry peers (median)−18%−49%−14%−2%+9%−12%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
GRCE33%17%33%58%58%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
GRCE−89%−76%−64%−38%−57%−65%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 99% from November 20, 2017 to September 22, 2023. Getting back needed a 8307% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.81 – $5.13
From 52-week high
−64.7%
vs 50-day average
−12.4%
vs 200-day average
−35.6%
Volatility (1 year)
72%
Beta vs S&P 500
0.92

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
7 up, 5 down
typical move ±1.9%
After a week
8 up, 4 down
typical move ±6.3%
After a month
8 up, 4 down
typical move ±13.7%
Results releasedNext dayS&P 500 next day5 days21 days
August 13, 2026 +2.9% +0.5% +1.9% +9.0%
June 18, 2026 +1.8% +0.7% +7.2% +9.5%
February 12, 2026 +0.6% −1.5% +8.1% +23.1%
November 13, 2025 +1.0% −1.7% +3.6% +6.9%
August 12, 2025 +5.8% +1.4% +6.1% +3.9%
June 23, 2025 0.0% +2.1% −1.0% +11.7%
February 13, 2025 −0.9% +1.1% −5.5% −34.2%
November 13, 2024 +3.8% −0.6% +2.8% +12.2%
August 9, 2024 −1.6% +0.5% +0.8% −2.5%
June 21, 2024 +1.6% −0.5% −7.3% −8.6%
February 12, 2024 −1.2% −1.4% +26.9% +38.8%
November 13, 2023 −1.8% +1.8% −4.5% −4.5%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$9M
Institutions reporting
33
Shares held vs prior quarter
▼ 7.4%
Positions opened / closed
10 / 11

Top buyers and sellers, Q2 2026: 22 institutions bought and 15 sold ; the biggest buyer was Citadel Advisors LLC (+251K shares) and the biggest seller Nantahala Capital Management, LLC (−728K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Cerity Partners LLC $1.9M 849K 21.5% 0.0%
Eversept Partners, LP $1.8M 773K 19.6% ▲ 2.2%
Bank Of America Corp $1.1M 495K 12.5% 0.0%
Vanguard Capital Management LLC $934,591 412K 10.4% ▲ 2.5%
Citadel Advisors LLC $793,910 350K 8.9% ▲ 254.2%
Cantor Fitzgerald, L. P. $454,000 200K 5.1% New
Maven Securities Ltd $454,000 200K 5.1% New
Birchview Capital, LP $272,400 120K 3.0% ▲ 140.0%
Two Sigma Investments, LP $219,940 97K 2.5% New
Jane Street Group, LLC $203,034 89K 2.3% ▼ 46.5%
Xtx Topco Ltd $162,686 72K 1.8% ▲ 13.6%
HRT Financial LP $142,000 63K 1.6% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Grace Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $806,243 21 trades by 2 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $806,243 net buying
Insider Date Trade Shares Price Value
Opaleye Management Inc. 10% owner October 26, 2026 Buy 66,411 $1.77 $117,408
Opaleye Management Inc. 10% owner October 22, 2026 Buy 21,390 $1.93 $41,193
Opaleye Management Inc. 10% owner October 19, 2026 Buy 4,256 $1.88 $8,001
Opaleye Management Inc. 10% owner October 16, 2026 Buy 36,347 $1.89 $68,758
Opaleye Management Inc. 10% owner October 15, 2026 Buy 23,485 $1.95 $45,685
Opaleye Management Inc. 10% owner October 14, 2026 Buy 11,233 $1.93 $21,735
Opaleye Management Inc. 10% owner October 12, 2026 Buy 7,215 $2.02 $14,574
Opaleye Management Inc. 10% owner October 9, 2026 Buy 5,340 $2.04 $10,918
Opaleye Management Inc. 10% owner October 8, 2026 Buy 2,077 $2.02 $4,190
Opaleye Management Inc. 10% owner October 5, 2026 Buy 1,694 $2.06 $3,490
Opaleye Management Inc. 10% owner October 2, 2026 Buy 20,000 $2.07 $41,368
Opaleye Management Inc. 10% owner October 1, 2026 Buy 38,796 $2.04 $78,961

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 12, 2026 estimated from the company's past filing pattern, not announced

  • August 13, 2026
  • June 18, 2026
  • February 12, 2026
  • November 13, 2025
  • August 12, 2025
  • June 23, 2025

Recent SEC filings

Data status

When each part of this page on Grace Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Grace Therapeutics, Inc. in brief

What does Grace Therapeutics, Inc. do?
Grace Therapeutics, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in March.
What is Grace Therapeutics, Inc.'s stock ticker?
Grace Therapeutics, Inc. trades under the ticker GRCE on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Grace Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Cerity Partners LLC, Eversept Partners, LP and Bank Of America Corp. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Grace Therapeutics, Inc. stock?
Over the last 12 months, Grace Therapeutics, Inc.'s directors and officers reported 21 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Grace Therapeutics, Inc.'s next earnings date?
Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Grace Therapeutics, Inc. announces its own schedule.